{"id":8694,"date":"2024-07-16T15:12:58","date_gmt":"2024-07-16T13:12:58","guid":{"rendered":"https:\/\/adragos-pharma.com\/?p=8694"},"modified":"2024-10-25T12:55:58","modified_gmt":"2024-10-25T10:55:58","slug":"future-pharma-new-and-existing-capabilities","status":"publish","type":"post","link":"https:\/\/adragos-pharma.com\/future-pharma-new-and-existing-capabilities\/","title":{"rendered":"The Future of Pharma: New and Existing Capabilities"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The <strong>pharmaceutical industry<\/strong> is experiencing a paradigm shift, driven by advancements in <strong>digital health<\/strong>, <strong>artificial intelligence<\/strong>, and <strong>precision medicine<\/strong>. The convergence of these technologies is paving the way for <strong>innovative medicines<\/strong>, <strong>disruptive technologies<\/strong>, and a more efficient <strong>healthcare system<\/strong>. This blog delves into the <strong>future of pharma<\/strong>, exploring new and existing capabilities, with a special focus on Adragos\u2019 facility in Athens, Greece, and the broader trends and challenges facing the <strong>pharmaceutical company<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Understanding Future Pharma<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>future of pharma<\/strong> encompasses a wide array of <strong>technologies<\/strong>, methodologies, and innovations aimed at improving patient outcomes, streamlining <strong>clinical trials<\/strong>, and enhancing the overall efficiency of the <strong>pharmaceutical industry<\/strong>. This includes advancements in <strong>gene therapy<\/strong>, <strong>preventive medicine<\/strong>, and <strong>digital health<\/strong> technologies, which are expected to revolutionize the way <strong>pharma companies<\/strong> operate and deliver value to patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-left\"><strong>The Heart of Innovation: Adragos Facility in Athens<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/adragos-pharma.com\/athens-greece\/\" rel=\"noopener noreferrer\">Adragos Athens<\/a>, formerly known as Lamda Laboratories, is at the forefront of these innovations. With more than 3,000 sqm of R&amp;D facilities, the site specializes in the development of <a href=\"https:\/\/adragos-pharma.com\/value-added-medicines\/\">Value Added Medicines (VAMs)<\/a> and has recently upgraded its capabilities to handle <a href=\"https:\/\/adragos-pharma.com\/drug-development\/hpapi\/\">Highly Potent Active Pharmaceutical Ingredients<\/a> (HPAPIs).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Additionally, with a highly experienced team of over 60 scientists, the facility has developed numerous innovative products and holds certifications under EU-GMP standards. The facility&#8217;s expertise spans <a href=\"https:\/\/adragos-pharma.com\/drug-development\/formulation-development\/\">formulation development<\/a>, <a href=\"https:\/\/adragos-pharma.com\/drug-development\/analytical-development\/\">analytical services<\/a>, <a href=\"https:\/\/adragos-pharma.com\/drug-development\/clinical-development\/\">scientific and clinical development<\/a>, <a href=\"https:\/\/adragos-pharma.com\/the-ultimate-guide-to-pharmaceutical-regulations\/\">regulatory services<\/a>, <a href=\"https:\/\/adragos-pharma.com\/our-services\/supply-chain-planning\/\">supply chain planning<\/a>, and <a href=\"https:\/\/adragos-pharma.com\/our-services\/controlled-drugs\/\">handling of controlled substances<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This makes Adragos Pharma a key player in the <strong>pharma ecosystem<\/strong>, providing essential services to both generic and specialty <strong>pharmaceutical companies<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The Evolution of Pharmaceutical Capabilities<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Formulation and Process Development<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">At Adragos Athens, <a href=\"https:\/\/adragos-pharma.com\/drug-development\/formulation-development\/\"><strong>formulation and process development<\/strong><\/a> activities are conducted in a GMP-like environment, mimicking full-scale manufacturing sites. This setup ensures seamless scale-up to different manufacturing sites, facilitating the production of high-quality pharmaceuticals. The facility is equipped with state-of-the-art small-scale R&amp;D equipment, which supports a wide range of techniques and capabilities.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Analytical and Stability Testing<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The GMP analytical laboratory at Adragos Athens is at the cutting edge of technology. It holds EU GMP approval and is prepared for FDA inspection, ensuring that all <a href=\"https:\/\/adragos-pharma.com\/drug-development\/analytical-development\/\" data-type=\"link\" data-id=\"https:\/\/adragos-pharma.com\/drug-product-development\/analytical-services\/\">analytical challenges <\/a>are met with precision and efficiency. The facility also houses Stability Chambers and Walk-In rooms to preserve samples for stability testing, further enhancing the <strong>quality<\/strong> and reliability of the pharmaceuticals developed.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Quality by Design (QbD)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Adragos Athens incorporates Quality by Design (QbD) into every development phase. By ensuring QbD touches each point of the commercial manufacturing process, Adragos is able to develop consistent, high-quality pharmaceutical products. This holistic approach is essential for meeting the stringent requirements of regulatory bodies and ensuring patient safety.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Dosage Forms and Specializations<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Adragos Athens offers a wide range of dosage forms, including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><p><strong>Oral<\/strong>: Tablets (Immediate Release and Modified Release), Capsules, Liquids, Effervescent Tablets, Orodispersible Tablets, Mini-Tablets, Multiparticulates<\/p><\/li>\n\n\n\n<li><p><strong>Parenteral<\/strong>: Solutions, Suspensions, Lyophilized products<\/p><\/li>\n\n\n\n<li><p><strong>Topical<\/strong>: Creams, Ointments, Gels, Ophthalmic, Nasal<\/p><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Future Trends in Pharma<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The pharmaceutical industry is continuously evolving, causing CDMO industries to stay always up-to-date with <a href=\"https:\/\/adragos-pharma.com\/key-trends-cdmo-industry\/\">the latest trends<\/a>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Digital Health and Artificial Intelligence<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The integration of <strong>digital health<\/strong> and <strong>artificial intelligence<\/strong> is transforming the <strong>pharmaceutical sector<\/strong>. AI-driven algorithms are being used to accelerate drug discovery, optimize clinical trial designs, and improve patient outcomes. <strong>Digital technologies<\/strong> are also enhancing <strong>customer engagement<\/strong>, enabling <strong>pharma companies<\/strong> to better understand patient needs and tailor treatments accordingly.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Precision Medicine and Gene Therapy<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Precision medicine<\/strong> and <strong>gene therapy<\/strong> represent the next frontier in personalized healthcare. These technologies allow for treatments to be tailored to individual patients based on their genetic makeup, leading to more effective and targeted therapies. This approach is particularly beneficial for rare diseases and complex conditions, where traditional treatments may fall short.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Preventive Medicine and Public Health<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The focus on <strong>preventive medicine<\/strong> is growing, with an emphasis on early detection and intervention to prevent disease progression. This shift is supported by advancements in <strong>real world evidence<\/strong> and <strong>digital health<\/strong> tools, which provide insights into patient behaviors and health outcomes. <strong>Pharma companies<\/strong> are leveraging these insights to develop preventive strategies and interventions that improve public health.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Challenges and Opportunities<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Navigating Regulatory Hurdles<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>pharmaceutical industry<\/strong> faces <strong>significant challenges<\/strong> in navigating complex regulatory environments. Compliance with EU GMP and FDA regulations requires continuous effort and adaptation. However, these challenges also present opportunities for <strong>pharma companies<\/strong> to innovate and improve their processes.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Embracing Disruptive Technologies<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The adoption of <strong>disruptive technologies<\/strong> such as blockchain, IoT, and AI is crucial for the <strong>future of pharma<\/strong>. These technologies enable better data management, enhance supply chain transparency, and improve patient safety. <strong>Pharma companies<\/strong> that embrace these technologies will be better positioned to compete in the evolving landscape.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Retaining Talent and Building Resilience<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">As the <strong>pharma industry<\/strong> evolves, attracting and <strong>retaining talent<\/strong> becomes increasingly important. Companies must invest in continuous learning and development to build a resilient workforce capable of adapting to new challenges and opportunities.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>future of pharma<\/strong> is bright, with new and existing capabilities driving the industry forward. Adragos Athens exemplifies the innovative spirit and commitment to excellence that will define the next generation of pharmaceutical advancements. As <strong>pharma companies<\/strong> continue to embrace <strong>digital health<\/strong>, <strong>artificial intelligence<\/strong>, and <strong>precision medicine<\/strong>, the industry is set to deliver unprecedented value to patients and the <strong>healthcare system<\/strong>.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-fe48e5de wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-secondary-background-color has-background wp-element-button\" href=\"https:\/\/adragos-pharma.com\/contact-us\/?utm_campaign=Banner_Blog_Articles&amp;utm_source=blog&amp;utm_medium=organic_search\">Do you want to know more about us?<\/a><\/div>\n<\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">FAQs about The Future of Pharma<\/h2>\n\n\n\n<div class=\"wp-block-gutena-accordion gutena-accordion-block gutena-accordion-block-a3ac81-81 is-layout-flow wp-block-gutena-accordion-is-layout-flow\" data-single=\"true\">\n<div class=\"wp-block-gutena-accordion-panel gutena-accordion-block__panel\">\n<div class=\"wp-block-gutena-accordion-panel-title gutena-accordion-block__panel-title\"><div class=\"gutena-accordion-block__panel-title-inner\">\n<h3 class=\"wp-block-heading has-text-align-left\" style=\"margin-top:0px;margin-right:0px;margin-bottom:0px;margin-left:0px\"><strong>How are digital health and AI transforming pharma?<\/strong><\/h3>\n<div class=\"trigger-up-down\"><div class=\"horizontal\"><\/div><div class=\"vertical\"><\/div><\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel-content gutena-accordion-block__panel-content\"><div class=\"gutena-accordion-block__panel-content-inner\">\n<p class=\"wp-block-paragraph\" style=\"margin-top:0;margin-bottom:0\"><strong>Digital health<\/strong> and <strong>artificial intelligence<\/strong> are enabling better drug discovery, optimizing <strong>clinical trials<\/strong>, and enhancing <strong>customer engagement<\/strong> by providing personalized treatment options.<\/p>\n<\/div><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel gutena-accordion-block__panel\">\n<div class=\"wp-block-gutena-accordion-panel-title gutena-accordion-block__panel-title\"><div class=\"gutena-accordion-block__panel-title-inner\">\n<h3 class=\"wp-block-heading has-text-align-left\" style=\"margin-top:0px;margin-right:0px;margin-bottom:0px;margin-left:0px\"><strong>What are the key trends in the pharmaceutical industry?<\/strong><\/h3>\n<div class=\"trigger-up-down\"><div class=\"horizontal\"><\/div><div class=\"vertical\"><\/div><\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel-content gutena-accordion-block__panel-content\"><div class=\"gutena-accordion-block__panel-content-inner\">\n<p class=\"wp-block-paragraph\" style=\"margin-top:0;margin-bottom:0\"><a href=\"https:\/\/adragos-pharma.com\/key-trends-cdmo-industry\/\">Key trends<\/a> include the rise of <strong>precision medicine<\/strong>, <strong>preventive medicine<\/strong>, the adoption of <strong>disruptive technologies<\/strong>, and a greater emphasis on patient-centric approaches.<\/p>\n<\/div><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel gutena-accordion-block__panel\">\n<div class=\"wp-block-gutena-accordion-panel-title gutena-accordion-block__panel-title\"><div class=\"gutena-accordion-block__panel-title-inner\">\n<h3 class=\"wp-block-heading has-text-align-left\" style=\"margin-top:0px;margin-right:0px;margin-bottom:0px;margin-left:0px\"><strong>How does Adragos Athens contribute to the future of pharma?<\/strong><\/h3>\n<div class=\"trigger-up-down\"><div class=\"horizontal\"><\/div><div class=\"vertical\"><\/div><\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel-content gutena-accordion-block__panel-content\"><div class=\"gutena-accordion-block__panel-content-inner\">\n<p class=\"wp-block-paragraph\" style=\"margin-top:0;margin-bottom:0\">Adragos Athens contributes by offering advanced R&amp;D capabilities, state-of-the-art analytical and stability testing, and a commitment to quality and innovation, ensuring the development of high-quality pharmaceutical products.<\/p>\n<\/div><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel gutena-accordion-block__panel\">\n<div class=\"wp-block-gutena-accordion-panel-title gutena-accordion-block__panel-title\"><div class=\"gutena-accordion-block__panel-title-inner\">\n<h3 class=\"wp-block-heading has-text-align-left\" style=\"margin-top:0px;margin-right:0px;margin-bottom:0px;margin-left:0px\"><strong>What are the challenges facing the pharmaceutical industry?<\/strong><\/h3>\n<div class=\"trigger-up-down\"><div class=\"horizontal\"><\/div><div class=\"vertical\"><\/div><\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-gutena-accordion-panel-content gutena-accordion-block__panel-content\"><div class=\"gutena-accordion-block__panel-content-inner\">\n<p class=\"wp-block-paragraph\" style=\"margin-top:0;margin-bottom:0\">The <strong>pharmaceutical industry<\/strong> faces challenges such as navigating regulatory hurdles, adopting <strong>new technologies<\/strong>, and <strong>retaining talent<\/strong>. However, these challenges also present opportunities for innovation and growth.<\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The pharmaceutical industry is experiencing a paradigm shift, driven by advancements in digital health, artificial intelligence, and precision medicine. The convergence of these technologies is paving the way for innovative medicines, disruptive technologies, and a more efficient healthcare system. This [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":8696,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[13],"tags":[],"topics":[26,78,27,36,38,24,25,28,37,34],"locations":[23],"experts":[],"class_list":["post-8694","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog","topics-analytical-services","topics-cdmo","topics-clinical-development","topics-controlled-drugs","topics-drug-stability-testing","topics-formulation-development","topics-highly-potent-api","topics-regulatory-services","topics-supply-chain-planning","topics-visual-inspection","locations-athens"],"_links":{"self":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/8694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/comments?post=8694"}],"version-history":[{"count":11,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/8694\/revisions"}],"predecessor-version":[{"id":13487,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/8694\/revisions\/13487"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/media\/8696"}],"wp:attachment":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/media?parent=8694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/categories?post=8694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/tags?post=8694"},{"taxonomy":"topics","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/topics?post=8694"},{"taxonomy":"locations","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/locations?post=8694"},{"taxonomy":"experts","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/experts?post=8694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}